Search
Blog Post
Cancer Innovations: Prioritizing quality of life while treating cancer
… the Cell Stress and Biophysical Therapy Program, and Emese Zsiros, MD, PhD, FACOG , Director of Research in the … more — and better quality — time with their loved ones Dr. Zsiros has spent the past several years researching the use … was 8-15%. The combination has a synergistic effect,” Dr. Zsiros says. “The typical treatments for ovarian cancer …
Blog Post
Why women with ovarian cancer should consider clinical trials
News
Roswell Park Team Assesses Addition of Complement Inhibitor Drug to Immunotherapy for Ovarian Cancer
… it has been evaluated for the treatment of cancer. Emese Zsiros, MD, PhD, FACOG , serves as principal investigator for … Research Project Grant (R01) awarded to Drs. Zsiros and Segal. “The tumor microenvironment of ovarian … cancer strongly suppresses the immune system,” says Dr. Zsiros, who is Chair of the Department of Gynecologic …
News
Roswell Park Researchers Uncover Clues to Immunotherapy Response in Patients with Recurrent Ovarian Cancer
Blog Post
Cancer Innovations: New initiative reduced prescribed opioids by 45%
… recovery. How would patients fare without opioids? Emese Zsiros, MD, PhD, FACOG, a gynecologic oncologist at Roswell … based on their clinical experience. The results? Dr. Zsiros says the number of opioids prescribed to these … in the fight against the ongoing opioid epidemic.” Dr. Zsiros and her team reported the results from the first six …
Cancer Types
Recurrent Ovarian Cancer
Clinical Trial
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY FOR LNCB74, A B7-H4 TARGETED ANTIBODY DRUG CONJUGATE, AS MONOTHERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Clinical Trial
A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety and Tolerability of GB-5267, an IL-18 Armored CAR T Cell Product Targeting MUC16, in Patients with Platinum-Resistant Ovarian Cancer
Cancer Types